Research and develop immuno-oncology and precision medicines. Commercialize innovative therapies for cancer treatment. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 37.1× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Sales run at $39.2M a year. A small number, but proof the product has real buyers.
A loss of $63.6M against $39.2M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.91. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.